The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Immune checkpoint blockade with PD-(L) 1 antibodies has revolutionized the treatment of
advanced non–small cell lung cancer (NSCLC). Similarly, the identification and targeting of …

Inhibitory antibodies targeting programmed death protein 1 (PD-1) and programmed death
ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Immunotherapy has dramatically changed the therapeutic scenario in treatment naïve
advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has …

Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer
(NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet …

Abstract Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely
used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI …

The outcomes for patients with previously treated advanced stage non–small lung cancer
(NSCLC) are very poor, with a modest benefit from chemotherapy over best supportive care …